Magle Chemoswed Holding AB (publ) (STO:MAGLE)

Market Cap	422.63M
Revenue (ttm)	290.43M
Net Income (ttm)	-20.16M
Shares Out	20.52M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	24.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,204
Average Volume	1,406
Open	20.80
Previous Close	21.20
Day's Range	20.40 - 21.80
52-Week Range	20.40 - 42.04
Beta	0.47
RSI	22.87
Earnings Date	Aug 1, 2025

About CTI BioPharma

Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease. The company also offers EmboCept S, a microsphere-based medical dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1944
• Employees: 147
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MAGLE

Financial Performance

In 2024, STO:MAGLE's revenue was 240.57 million, an increase of 40.27% compared to the previous year's 171.50 million. Earnings were 11.94 million, a decrease of -1.91%.